Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens

Next Previous
Trial Profile

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TROPICS-02
  • Sponsors Gilead Sciences; Immunomedics

Most Recent Events

  • 30 Apr 2025 Results assessing specific mutations at BSL and EOT in TROPiCS-02 to identify genes that may be involved in acquired SG resistance, presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 06 Sep 2024 Results presenting health-related quality of life (HRQoL) patient-reported outcome (PRO) findings from this study published in the Oncologist
  • 04 Jun 2024 Results assessing comprehensive genomic analysis of DDR gene variants and impact on SG clinical efficacy in this patient population presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top